AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38092790
Drug: Mazdutide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazdutide (up to 6 mg)
Trial: 38092871
Drug: Elevated choline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated choline levels (per SD, 11.49 μg/mL)
Trial: 38092897
Drug: AP30663, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP30663, an inhibitor of the K channel
Trial: 38093181
Drug: Low eosinophil
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low eosinophil count <0.01 G/L
Trial: 38093181
Drug: Eosinophil count
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eosinophil count 0-0.07 G/L
Trial: 38093181
Drug: Eosinophil count
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eosinophil count 0.07-0.172 G/L
Trial: 38093181
Drug: Eosinophil count
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eosinophil count <0.01 G/L
Trial: 38093439
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (Hgb threshold 7.0 g/dL)
Trial: 38093439
Drug: Conservative transfusion
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative transfusion strategy (Hgb threshold 5.5 g/dL)
Trial: 38093803
Drug: internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-delivered cognitive behavioural therapy (iCBT) program for 9 weeks
Trial: 38094620
Drug: FFT-MCC (Family-focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFT-MCC (Family-focused therapy with MyCoachConnect app)
Trial: 38094620
Drug: FFT-Track (Family-focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFT-Track (Family-focused therapy with mood tracking only)
Trial: 38094629
Drug: Tumor Treating
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor Treating Fields (TTFields) therapy
Trial: 38095657
Drug: Survodutide (dose-response
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survodutide (dose-response effects)
Trial: 38095692
Drug: Ustekinumab (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (90 mg every 8 or 12 weeks)
Trial: 38095878
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and atezolizumab (1200 mg every 3 weeks)
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy with bevacizumab
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy without bevacizumab
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy with carboplatin
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy with cisplatin
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy with prior CRT
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy without prior CRT
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy in squamous type
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy in nonsquamous type
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy with bevacizumab (intention-to-treat)
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy without bevacizumab (intention-to-treat)
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy with carboplatin (intention-to-treat)
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy with cisplatin (intention-to-treat)
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy with prior CRT (intention-to-treat)
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy without prior CRT (intention-to-treat)
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy in squamous type (intention-to-treat)
Trial: 38095881
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy in nonsquamous type (intention-to-treat)
Trial: 38095903
Drug: Weighted combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weighted combination of clinical predictors
Trial: 38095899
Drug: Evidence-based checklist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based checklist administered every 6 hours from enrollment to organ retrieval.
Trial: 38096002
Drug: Weekly medication
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly medication diary and standardized self-reports (both groups)
Trial: 38096102
Drug: MKI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MKI therapy (cohort 1)
Trial: 38096102
Drug: Active surveillance
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active surveillance transitioning to MKI therapy (cohort 2)
Trial: 38096105
Drug: Adjunctive systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive systemic corticosteroids
Trial: 38096461
Drug: Obinutuzumab (G)
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab (G) plus chemotherapy (bendamustine, CHOP, or CVP)
Trial: 38096461
Drug: Rituximab (R)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (R) plus chemotherapy (bendamustine, CHOP, or CVP)
Trial: 38096462
Drug: PEG-L-Asparaginase (PEG-ASNASE,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-L-Asparaginase (PEG-ASNASE, 2,500 IU/sqm once a week × 4)
Trial: 38096705
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin ± amoxicillin
Trial: 38096705
Drug: Antibiotic receipt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic receipt per physician discretion (vs for cesarean prophylaxis)
Trial: 38096705
Drug: 3 factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 factor model (cesarean birth, receipt of antibiotics per physician discretion, university education)
Trial: 38097741
Drug: Olaparib (O)
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib (O) maintenance therapy
Trial: 38098024
Drug: Matched-pair group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched-pair group receiving coated implant
Trial: 38098221
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 400 mg/day for 3 days and 200 mg/day for 11 days
Trial: 38098734
Drug: Digital Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital Therapy for Obesity App (DTxO)
Trial: 38099081
Drug: Accelerated high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated high-dose theta burst stimulation (ahTBS)
Trial: 38099673
Drug: GST-HG171 (150-900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GST-HG171 (150-900 mg single ascending doses)
Trial: 38099673
Drug: GST-HG171 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GST-HG171 (150 and 300 mg multiple ascending doses)
Trial: 38099673
Drug: GST-HG171/ritonavir (150/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GST-HG171/ritonavir (150/100 mg BID for 5 days)
Trial: 38099673
Drug: GST-HG171/ritonavir (150/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GST-HG171/ritonavir (150/100 mg BID)
Trial: 38100078
Drug: Diquafosol Sodium
DrugBank: Diquafosol (DB15919)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Diquafosol Sodium Ophthalmic Solution, dosage and duration not available
Trial: 38100110
Drug: Azithromycin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (single dose, biannual administration over 2 years)
Trial: 38100110
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo, biannual administration over 2 years)
Trial: 38100172
Drug: Health education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health education program including face-to-face counseling on lifestyle modifications, blood pressure monitoring, and medication compliance-related health education during enrollment and monthly follow-ups.
Trial: 38100536
Drug: Recombinant vaccinia
RxNorm normalized name: Dna (recombinant vaccinia virus strain livp clone gl-onc1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant vaccinia virus expressing Nipah virus glycoprotein (G)
Trial: 38100679
Drug: Mepolizumab 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 300 mg subcutaneously every four weeks
Trial: 38101301
Drug: AADvac1 (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AADvac1 (active immunotherapy against pathological tau protein)
Trial: 38101431
Drug: Atezolizumab monotherapy
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab monotherapy (1200 mg IV every 3 weeks)
Trial: 38101429
Drug: Lipid-lowering medication
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering medication (LLM) usage
Trial: 38101824
Drug: 4-day intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day intensive cognitive behavioural therapy (B4DT)
Trial: 38101824
Drug: Individual cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive behavioural therapy (standard CBT)
Trial: 38101830
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) with deproteinisation using Papacárie Duo
Trial: 38101830
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) with deproteinisation using 5% sodium hypochlorite solution
Trial: 38101840
Drug: Potassium binders
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium binders (PB) treatment for hyperkalaemia (HK)
Trial: 38101850
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) programme
Trial: 38101851
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) administered at primary motor cortex
Trial: 38101851
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) administered at primary sensory cortex
Trial: 38101851
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) administered at dorsolateral prefrontal cortex
Trial: 38101860
Drug: pTVG-HP (100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pTVG-HP (100 µg administered intradermally) and nivolumab (240 mg intravenous infusion) every 2 weeks for 3 months, then every 4 weeks for 1 year.
Trial: 38101901
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg NLY01
Trial: 38101901
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg NLY01
Trial: 38102226
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg/d
Trial: 39695798
Drug: 7-day antimicrobial
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day antimicrobial therapy
Trial: 39695798
Drug: 14-day antimicrobial
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day antimicrobial therapy
Trial: 38102496
Drug: BRIGHT (cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRIGHT (cognitive behavioral therapy)
Trial: 38102536
Drug: Supervised concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised concurrent group (SCG, n=30)
Trial: 38102544
Drug: Clinical pharmacists'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacists' medication reconciliation
Trial: 38102544
Drug: Emergency physicians'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency physicians' medication reconciliation
Trial: 38102544
Drug: Clinical pharmacists'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacists' written copy of drug history
Trial: 38102544
Drug: Medication discrepancies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication discrepancies detected
Trial: 38102544
Drug: Relationship between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relationship between discrepancies and comorbidities/drugs
Trial: 38102687
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg methylprednisolone intravenous bolus over 5 minutes
Trial: 38103784
Drug: Yoga-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga-based intervention (YBI) with personal practice videos, private sessions, daily text messages, and monetary incentives
Trial: 38103842
Drug: Camostat 100
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat 100 mg 3 times daily
Trial: 38103842
Drug: Camostat 200
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat 200 mg 3 times daily
Trial: 38103842
Drug: Camostat 300
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat 300 mg 3 times daily
Trial: 38103947
Drug: Cabozantinib 20
RxNorm normalized name: cabozantinib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 20 mg (DL 0) or 40 mg (DL 1) daily on days 1-28 combined with FTD/TPI 35 mg/m².
Trial: 38103947
Drug: Cabozantinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib and FTD/TPI combination treatment.
Trial: 38103956
Drug: Pencil beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pencil beam scanning proton therapy with a simultaneous integrated boost (SIB) approach and at least 1 rescan evaluation during the first 5 ± 2 fractions.
Trial: 38104036
Drug: Imatinib (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (first-line treatment, 69.9% of patients)
Trial: 38104036
Drug: General TKI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General TKI treatment adherence
Trial: 38104036
Drug: Impact of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impact of COVID-19 on treatment
Trial: 38104131
Drug: Flutamide (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (administered orally 6-12 hours prior to prostate biopsy)
Trial: 38104145
Drug: Proactive opioid-sparing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive opioid-sparing analgesic protocol
Trial: 38104538
Drug: Non-anuric participants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-anuric participants (cumulative 24 h UO at inclusion ≥0.05 mL kg-1 h-1)
Trial: 38104538
Drug: Anuric participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anuric participants (cumulative 24 h UO at inclusion <0.05 mL kg-1 h-1)
Trial: 38104569
Drug: guselkumab 200→100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 200→100 mg
Trial: 38104569
Drug: guselkumab 600→200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 600→200 mg
Trial: 38104569
Drug: guselkumab 1200→200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 1200→200 mg
Trial: 38105142
Drug: Sitravatinib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitravatinib (120 mg QD or 100 mg QD) plus Nivolumab (240 mg every 2 weeks or 480 mg every 4 weeks)
Trial: 38105505
Drug: Tiragolumab (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab (2, 8, 30, 100, 400, 600, or 1200 mg) followed by atezolizumab (1200 mg)
Trial: 38105505
Drug: Tiragolumab (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab (840 mg) followed by atezolizumab (1680 mg)
Trial: 38105505
Drug: Tiragolumab (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab (840 mg) plus atezolizumab (1680 mg)
Trial: 38105911
Drug: 0.25% reproxalap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% reproxalap ophthalmic solution
Trial: 38106133
Drug: Genotype-driven guidance
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-driven guidance of antiplatelet therapy
Trial: 38106555
Drug: Zapnometinib (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zapnometinib (900 mg on Day 1; 600 mg on Days 2-6)
Trial: 38106564
Drug: Zotarolimus-eluting drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotarolimus-eluting drug-eluting stent
Trial: 38106570
Drug: Iptacopan (10-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iptacopan (10-100 mg for days 1-21, 200 mg for days 22-84)
Trial: 38107263
Drug: Early changes
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early changes in sensitive echo indices (e.g., global longitudinal strain) and cardiac biomarkers (e.g., troponin and natriuretic peptides)
Trial: 38107263
Drug: Expert consensus-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expert consensus-based strategies in cardiac monitoring and anthracycline dose modification
Trial: 38107366
Drug: Postoperative analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative analgesic usage
Trial: 38107366
Drug: Well-being assessment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Well-being assessment using EQ-5D-5 L
Trial: 38107443
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon beta-1a or peginterferon beta-1a therapy (IFN)
Trial: 38107482
Drug: Mg citrate
RxNorm normalized name: K-Mg Citrate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg citrate supplementation
Trial: 38107641
Drug: Therapeutic Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic Chinese massage (TCM) - three weekly 25-min sessions
Trial: 38107641
Drug: Placebo massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo massage sessions - three weekly 25-min sessions
Trial: 38107829
Drug: Adjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant endocrine therapy (86.5%, 45/52)
Trial: 38107829
Drug: Chemotherapy (83.3%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (83.3%, 40/48)
Trial: 38107829
Drug: Capecitabine monotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine monotherapy (62.5%, 25/40)
Trial: 38109170
Drug: Technology as
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Technology as an aide to daily self-management.
Trial: 38109364
Drug: Rifaximin (antibiotic)
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin (antibiotic)
Trial: 38109921
Drug: nOPV2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nOPV2 vaccine administered at a 0.1 mL dose with a 1-week interval (group A)
Trial: 38109921
Drug: nOPV2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nOPV2 vaccine administered at a 0.1 mL dose with a 2-week interval (group B)
Trial: 38109921
Drug: nOPV2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nOPV2 vaccine administered at a 0.1 mL dose with a 4-week interval (group C)
Trial: 38109921
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups after 2 doses of nOPV2
Trial: 38109921
Drug: nOPV2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nOPV2 vaccine